Dr. Stephen Nimer on MSI2 as a Requirement for Maintaining Activated MDS Stem Cells
Stephen Nimer, MD, leukemia and lymphoma treatment specialist, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses results of a study which examined Musashi2 as a requirement for maintaining activated myelodysplastic syndrome (MDS) cells.
Stephen D. Nimer, MD, leukemia and lymphoma treatment specialist, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses results of a study which examined Musashi2 (MSI2) as a requirement for maintaining activated myelodysplastic syndrome (MDS) cells. MSI2 is an RNA-binding protein expressed in hematopoietic stem cell.
Studies in MSI2 have shown that as MDS progresses to AML, cells express higher levels of MSI2, suggesting that MSI2 must confer some benefit to the cells, according to Nimer. He adds that without MSI2, MDS cannot be sustained, while on the other end of the spectrum, patients with an overabundance of MSI2 quickly develop leukemia.
Selection of Next-Gen BTK in CLL Limited By Lack of Direct Comparison
February 4th 2025During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK inhibitor therapies acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia who received 1 prior line of therapy in the second article of a 2-part series.
Read More
